Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Haipeng Xu, Xueyan Chen, Dong Lin, Jing Zhang, Chao Li, Dianbao Zhang & Xianfen Zhang. (2019) Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer. OncoTargets and Therapy 12, pages 11541-11547.
Read now
Read now
Jiali Yang, Juan Chen, Jun Wei, Xiaoming Liu & William C. Cho. (2016) Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Expert Opinion on Biological Therapy 16:10, pages 1209-1223.
Read now
Read now
Articles from other publishers (20)
Michael Owyong, Yair Lotan, Payal Kapur, Vandana Panwar, Tiffani McKenzie, Thomas K. Lee, Xiaolin Zi, Jeremy W. Martin, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoneim & Ramy F. Youssef. (2019) Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations 37:7, pages 478-484.
Crossref
Crossref
Karolina Edlund, Katrin Madjar, Johanna S.M. Mattsson, Dijana Djureinovic, Cecilia Lindskog, Hans Brunnström, Hirsh Koyi, Eva Brandén, Karin Jirström, Fredrik Pontén, Jörg Rahnenführer, Patrick Micke & Jan G. Hengstler. (2019) Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. Journal of Thoracic Oncology 14:4, pages 628-640.
Crossref
Crossref
Giuseppe Troiano, Vito C. A. Caponio, Khrystyna Zhurakivska, Claudia Arena, Giuseppe Pannone, Marco Mascitti, Andrea Santarelli & Lorenzo Lo Muzio. (2018) High PD‐L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta‐analysis of the literature. Cell Proliferation 52:2.
Crossref
Crossref
Konrad Pawelczyk, Aleksandra Piotrowska, Urszula Ciesielska, Karolina Jablonska, Natalia Gletzel-Plucinska, Jedrzej Grzegrzolka, Marzenna Podhorska-Okolow, Piotr Dziegiel & Katarzyna Nowinska. (2019) Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers. International Journal of Molecular Sciences 20:4, pages 824.
Crossref
Crossref
Tomoyuki Miyazawa, Hideki Marushima, Hisashi Saji, Koji Kojima, Masahiro Hoshikawa, Masayuki Takagi & Haruhiko Nakamura. (2019) PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. Annals of Thoracic and Cardiovascular Surgery 25:1, pages 1-9.
Crossref
Crossref
Maureen L. Drakes, Swati Mehrotra, Monica Aldulescu, Ronald K. Potkul, Yueying Liu, Anne Grisoli, Cara Joyce, Timothy E. O’Brien, M. Sharon Stack & Patrick J. Stiff. (2018) Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. Journal of Ovarian Research 11:1.
Crossref
Crossref
Ashley Volaric, Ryan Gentzler, Richard Hall, James H. Mehaffey, Edward B. Stelow, Timothy N. Bullock, Linda W. Martin & Anne M. Mills. (2018) Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer. American Journal of Surgical Pathology 42:9, pages 1216-1223.
Crossref
Crossref
Alexander T. Falk, Nathalie Yazbeck, Nicolas Guibert, Emmanuel Chamorey, Agnès Paquet, Lydia Ribeyre, Coraline Bence, Katia Zahaf, Sylvie Leroy, Charles-Hugo Marquette, Charlotte Cohen, Baharia Mograbi, Julien Mazières, Véronique Hofman, Patrick Brest, Paul Hofman & Marius Ilié. (2018) Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. Lung Cancer 121, pages 70-75.
Crossref
Crossref
Guangzhi Ma, Yunfu Deng, Hai Jiang, Wen Li, Qiang Wu & Qinghua Zhou. (2018) The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. Clinica Chimica Acta 482, pages 101-107.
Crossref
Crossref
Boris Sepesi, David B. Nelson, Kyle G. Mitchell, Don L. Gibbons, John V. Heymach, Ara A. Vaporciyan, Stephen G. Swisher & Jason Roszik. (2018) Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 105:6, pages 1621-1626.
Crossref
Crossref
M. Ilié, E. Szafer-Glusman, V. Hofman, E. Chamorey, S. Lalvée, E. Selva, S. Leroy, C.-H. Marquette, M. Kowanetz, P. Hedge, E. Punnoose & P. Hofman. (2018) Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Annals of Oncology 29:1, pages 193-199.
Crossref
Crossref
Akito Hata, Nobuyuki Katakami, Shigeki Nanjo, Chiyuki Okuda, Reiko Kaji, Katsuhiro Masago, Shiro Fujita, Hiroshi Yoshida, Kota Zama, Yukihiro Imai & Yukio Hirata. (2017) Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer. Lung Cancer 111, pages 182-189.
Crossref
Crossref
Minghui Zhang, Guoliang Li, Yanbo Wang, Yan Wang, Shu Zhao, Pu Haihong, Hongli Zhao & Yan Wang. (2017) PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Scientific Reports 7:1.
Crossref
Crossref
Ji Li, Ping Wang & Youliang Xu. (2017) Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. PLOS ONE 12:6, pages e0179536.
Crossref
Crossref
Aaron T. Mayer, Arutselvan Natarajan, Sydney R. Gordon, Roy L. Maute, Melissa N. McCracken, Aaron M. Ring, Irving L. Weissman & Sanjiv S. Gambhir. (2017) Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. Journal of Nuclear Medicine 58:4, pages 538-546.
Crossref
Crossref
Erna-Elise Paulsen, Thomas K. Kilvaer, Mehrdad Rakaee Khanehkenari, Samer Al-Saad, Sigurd M. Hald, Sigve Andersen, Elin Richardsen, Nora Ness, Lill-Tove Busund, Roy M. Bremnes & Tom Donnem. (2017) Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach. Clinical Lung Cancer 18:2, pages 220-233.e8.
Crossref
Crossref
Michaël Duruisseaux, Isabelle Rouquette, Julien Adam, Alexis Cortot, Aurélie Cazes, Laure Gibault, Diane Damotte & Sylvie Lantuejoul. (2017) Efficacité des inhibiteurs du checkpoint immunitaire PD-1/PD-L1 et testing PD-L1 dans les cancers thoraciques. Annales de Pathologie 37:1, pages 61-78.
Crossref
Crossref
Claud Grigg & Naiyer A. Rizvi. (2016) PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. Journal for ImmunoTherapy of Cancer 4:1.
Crossref
Crossref
Xue Li, Minghuan Li, Zhen Lian, Hui Zhu, Li Kong, Ping Wang & Jinming Yu. (2016) Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. Targeted Oncology 11:6, pages 753-761.
Crossref
Crossref
Kentaro Inamura, Yusuke Yokouchi, Rie Sakakibara, Maki Kobayashi, Sophia Subat, Hironori Ninomiya, Hiroko Nagano, Kimie Nomura, Sakae Okumura & Yuichi Ishikawa. (2016)
Relationship of tumor PD-L1 expression with
EGFR
wild-type status and poor prognosis in lung adenocarcinoma
. Japanese Journal of Clinical Oncology 46:10, pages 935-941.
Crossref
Crossref